Real‐world evidence confirms thrombopoietin receptor agonists are safe and effective for all stages of immune thrombocytopenia
American Journal of Hematology · 2024
DOI: 10.1002/ajh.27129 ↗Kurz gefasst
Kommentar in der Zeitschrift American Journal of Hematology, 2024. Verfasst von Drew Provan. Beteiligte Einrichtung: Centre for Immunology, Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK. Hauptthemen laut MEDLINE: Purpura, Thrombocytopenic, Idiopathic, Thrombocytopenia. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 6 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Centre for Immunology, Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.
ORCID-Profile: Drew Provan
Zitieren
APA
Provan, D. (2024). Real‐world evidence confirms thrombopoietin receptor agonists are safe and effective for all stages of immune thrombocytopenia. American Journal of Hematology. https://doi.org/10.1002/ajh.27129
Vancouver
Provan D. Real‐world evidence confirms thrombopoietin receptor agonists are safe and effective for all stages of immune thrombocytopenia. American Journal of Hematology. 2024. doi:10.1002/ajh.27129
BibTeX
@article{Provan2024,
author = {Provan, Drew},
title = {Real‐world evidence confirms thrombopoietin receptor agonists are safe and effective for all stages of immune thrombocytopenia},
journal = {American Journal of Hematology},
year = {2024},
doi = {10.1002/ajh.27129}
}
EUVIMED